Halozyme Therapeutics Aktie

68,04 EUR +0,24 EUR +0,35 %

17:32:07

STU

80,67 USD +1,22 USD +1,54 %

17:41:28

BTT

Halozyme Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.7,89 Mrd. EUR

KGV13,93Div. Rendite0,00%

WKNA0DLHS

ISINUS40637H1095

SymbolHALO

Halozyme Therapeutics Aktien News

Sortieren:Datum Meistgelesen

16.02.26BenzingaEarnings Preview: Halozyme Therapeutics

16.02.26ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

16.02.26ZacksHere's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today

WerbungHalozyme Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

13.02.26ZacksStay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics

10.02.26ZacksHalozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth

04.02.26ZacksWhy Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

02.02.26ZacksWill Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

30.01.26ZacksWhy Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

30.01.26ZacksIf You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

28.01.26BenzingaHalozyme Therapeutics Projects Sustained Growth Well Into 2040

20.01.26MotleyFoolHalozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty

13.01.26ZacksHalozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?

08.01.26PR NewswireHalozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

05.01.26PR NewswireHalozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

19.12.25ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

18.12.25PR NewswireU.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

09.12.25ZacksWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

08.12.25PR NewswireJim Lang Elected to Halozyme's Board of Directors

03.12.25ZacksWhy Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?

01.12.25ZacksWhat Makes Halozyme Therapeutics (HALO) a New Buy Stock

01.12.25ZacksIf You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

27.11.25ZacksWhy Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

25.11.25PR NewswireHalozyme to Participate in the 8th Annual Evercore Healthcare Conference

18.11.25PR NewswireHalozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

17.11.25PR NewswireMerus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

07.11.25PR NewswireFDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

05.11.25MotleyFoolRenaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

04.11.25ZacksHalozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

03.11.25ZacksHalozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

03.11.25PR NewswireHALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

27.10.25ZacksHalozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

21.10.25PR NewswireHalozyme to Report Third Quarter 2025 Financial and Operating Results

20.10.25ZacksWill Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

17.10.25ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

15.10.25BenzingaThe Analyst Verdict: Halozyme Therapeutics In The Eyes Of 10 Experts

01.10.25PR NewswireHalozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

25.09.25ZacksWhy Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

24.09.25ZacksZacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience

23.09.25ZacksHalozyme Therapeutics and Synopsys have been highlighted as Zacks Bull and Bear of the Day

23.09.25ZacksBull of the Day: Halozyme Therapeutics (HALO)

Halozyme Therapeutics News

Halozyme Therapeutics News: auf dieser Seite finden Sie alle Halozyme Therapeutics News und Nachrichten zur Halozyme Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Halozyme Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Halozyme Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.